Topaz raises $20M in first round

Philadelphia-based Topaz Pharmaceuticals has raised $20 million in Series A financing from Aisling Capital and Fidelity Biosciences. The funds will be used to help Topaz complete clinical trials of the company's new prescription medicine to fight head lice, which are becoming more resistant to some traditional treatments. The funding will also be used to prepare the product for market.

- check out the release from Topaz

ALSO: Cambridge, MA-based Merrimack Pharmaceuticals has raised $35 million of an $80 Series F financing round. Investors in the round were not disclosed. Report

PLUS: Evalve, a developer devices for the percutaneous repair of cardiac valves, has completed a $60 million Series D financing. Release

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.